332 related articles for article (PubMed ID: 27430123)
1. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
[TBL] [Abstract][Full Text] [Related]
2. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes.
Hui JS; Fox SH; Neeson W; Bhargava P; Pappert E; Blum D; Navia B;
Parkinsonism Relat Disord; 2020 Oct; 79():110-116. PubMed ID: 32927285
[TBL] [Abstract][Full Text] [Related]
3. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
4. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
Kassubek J; Factor SA; Balaguer E; Schwarz J; Chaudhuri KR; Isaacson SH; Wu S; Denecke Muhr C; Kulisevsky J
J Neurol; 2024 Jun; 271(6):3554-3570. PubMed ID: 38546829
[TBL] [Abstract][Full Text] [Related]
6. Sublingual apomorphine in treatment of Parkinson's disease: a review.
Hislop J; Margolesky J; Shpiner DS
Int J Neurosci; 2024 May; 134(5):474-480. PubMed ID: 35986574
[TBL] [Abstract][Full Text] [Related]
7. Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease.
Olanow CW; Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Navia B
Parkinsonism Relat Disord; 2021 Dec; 93():27-30. PubMed ID: 34763305
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.
LeWitt PA; Hauser RA; Grosset DG; Stocchi F; Saint-Hilaire MH; Ellenbogen A; Leinonen M; Hampson NB; DeFeo-Fraulini T; Freed MI; Kieburtz KD
Mov Disord; 2016 Sep; 31(9):1356-65. PubMed ID: 27090868
[TBL] [Abstract][Full Text] [Related]
9. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
[TBL] [Abstract][Full Text] [Related]
10. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362
[TBL] [Abstract][Full Text] [Related]
11. Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study.
Grosset KA; Malek N; Morgan F; Grosset DG
J Parkinsons Dis; 2013; 3(1):31-7. PubMed ID: 23938309
[TBL] [Abstract][Full Text] [Related]
12. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
[TBL] [Abstract][Full Text] [Related]
13. On demand therapy for Parkinson's disease patients: Opportunities and choices.
Hauser RA; LeWitt PA; Comella CL
Postgrad Med; 2021 Sep; 133(7):721-727. PubMed ID: 34082655
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study.
Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Lockhart D; Staines H; Lees A
Parkinsonism Relat Disord; 2021 Feb; 83():79-85. PubMed ID: 33486139
[TBL] [Abstract][Full Text] [Related]
15. Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease.
Stocchi F; Berardelli A; Vacca L; Barbato L; Monge A; Nordera G; Ruggieri S
Clin Neuropharmacol; 2003; 26(3):151-5. PubMed ID: 12782918
[TBL] [Abstract][Full Text] [Related]
16. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
Maggio R; Barbier P; Corsini GU
J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
[TBL] [Abstract][Full Text] [Related]
17. Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes.
Isaacson SH; Bowling A; Zhang I; Pappert E; Stocchi F;
Neurodegener Dis Manag; 2023 Apr; 13(2):75-84. PubMed ID: 36562349
[No Abstract] [Full Text] [Related]
18. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
Colzi A; Turner K; Lees AJ
J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
[TBL] [Abstract][Full Text] [Related]
19. Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study.
Stocchi F; Rascol O; Poewe W; Chaudhuri KR; Kassubek J; Lopez Manzanares L; Zhang Y; Bowling A; Pappert E; Wu S;
J Parkinsons Dis; 2023; 13(8):1329-1342. PubMed ID: 37980683
[TBL] [Abstract][Full Text] [Related]
20. Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.
Rascol O; Azulay JP; Blin O; Bonnet AM; Brefel-Courbon C; Césaro P; Damier P; Debilly B; Durif F; Galitzky M; Grouin JM; Pennaforte S; Villafane G; Yaici S; Agid Y
Mov Disord; 2010 Feb; 25(3):368-76. PubMed ID: 20063435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
